Heat thErapy And mobiLity in COVID-19 Survivors

NCT ID: NCT06928116

Last Updated: 2025-10-23

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 99 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-17
• Study Completion Date: 2029-08-31

Brief Summary

Post-acute sequelae of SARS-CoV-2 infection (PASC) is becoming a major risk factor for chronic diseases, with older adults and those with underlying health conditions at risk of developing persistent mobility limitations and disabilities. Although exercise intervention is a common strategy to restore functional capacity, it may not be feasible or enticing to many people with PASC. This clinical trial seeks to establish the tolerability and efficacy of at home lower-body heat therapy for improving functional capacity along with metabolic and vascular health in late-middle aged and older adults with PASC, also known as "long COVID".

Detailed Description

Post-acute sequelae of SARS-CoV-2 infection (PASC) affects 5 out of 10 patients hospitalized for the coronavirus disease 2019 (COVID-19) and ~11% of all adults infected by SARS-CoV-2, which makes this condition a growing public health concern. It is associated with important disabilities, cognitive dysfunction, and increased risks for cardiovascular and metabolic diseases. Although exercise-based intervention is a promising rehabilitation strategy, participation rates are commonly low in clinical population. In addition, post-exertional malaise, a common symptom with PASC, is a major safety concern in these patients, which may prevent a significant proportion of these individuals to receive adequate rehabilitation. In this context, there is a critical need to develop well-tolerated and effective strategies at home that ameliorates health and functional capacity in individuals with PASC. One promising approach that offers numerous health benefits is whole-body heat therapy. Whether this intervention is effective when confined to the lower body and well tolerated at home in people with PASC is, however, unknown.

The overall objective of this project is to determine the safety, tolerability, and efficacy of home-based lower body heat therapy in late middle-age and older adults with PASC. Investigators will test the central hypothesis that home-based lower body heat therapy is safe, well adhered, and can improve functional capacity and several surrogate markers for metabolic and vascular health in late-middle age and older adults with PASC. Specific Aim 1 will test the hypothesis that lower body heat therapy at home is safe, well adhered, and improve both cognitive and physical function in middle-age and older adults with PASC. Selected participants will be randomly allocated to perform 8 weeks of home-based lower body heat therapy (HT, skin temperature 38-40˚C, 40-55 min, 5 per week at home), a thermoneutral condition (CT, skin temperature 33˚C, same duration and frequency), or a walking intervention using wearable technology (WT, 1,500-3,000 additional steps from baseline, 3-5 days per week). We will compare the 6 min walking distance, the short physical performance battery test score, gait speed, cognitive function, incidence of adverse events, and participant's adherence to intervention between groups. Specific Aim 2 will test the hypothesis that heat therapy will attenuate inflammation, which will then decrease arterial stiffness, and improve both vascular endothelial function and muscle intracellular oxygen availability in participants with PASC. Investigators will use in vitro assays on blood samples and Doppler ultrasound techniques to assess changes in inflammation, redox status, pulse-wave velocity, and flow-mediated dilation. Muscle intracellular oxygen availability will be measured by magnetic resonance spectroscopy in vivo. Specific Aim 3 will test the hypothesis that lower body heat therapy will improve glucose control as a result of enhanced mitochondrial function. All these effects will not be statistically inferior to the WT group. The proposed research is highly significant as it is easily translatable and is expected to guide future rehabilitation strategies to mitigate long-term disabilities in patients with PASC.

Conditions

Long COVID

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Heat Therapy

At home heat therapy 5 times (40-55 min) per week for 8 weeks.

Group Type: EXPERIMENTAL

Heat therapy

Intervention Type: BEHAVIORAL

At home lower body heat therapy

Control Therapy

Sham at home thermoneutral therapy 5 times (40-55 min) per week for 8 weeks.

Group Type: SHAM_COMPARATOR

Sham Control

Intervention Type: BEHAVIORAL

Sham Thermoneutral

Walking Intervention Using Wearable Technology

+1,500-3000 steps per day 3-5 days a week for 8 weeks.

Group Type: ACTIVE_COMPARATOR

Walking

Intervention Type: BEHAVIORAL

Walking intervention

Interventions

Heat therapy

At home lower body heat therapy

Intervention Type: BEHAVIORAL

Sham Control

Sham Thermoneutral

Intervention Type: BEHAVIORAL

Walking

Walking intervention

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Between the ages of 50 and 90 years
• Free from orthopedic limitations that would prohibit performing leg exercise
• BMI < 40 kg/m2 and weigh < 400lbs
• Previously contracted Covid-19 and have persistent symptoms such as a fatigue or decline in physical function, for at least 2 months following SARS-CoV-2 infection

Exclusion Criteria

• Unable to give written informed consent
• Women who are pregnant, breastfeeding, or likely to become pregnant within the next 6 months
• Women who are taking hormone therapy
• Claustrophobia
• Orthopedic limitations that would prohibit them from walking
• Currently enrolled in an exercise-based or respiratory muscle rehabilitation program.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Aging (NIA)

NIH

Sponsor Role: collaborator

University of Nebraska

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gwenael Layec, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Nebraska

Locations

University of Nebraska Omaha

Omaha, Nebraska, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Gwenael Layec, PhD

Role: CONTACT

unovrl@unomaha.edu

402-554-3779

Facility Contacts

Gwenael Layec, PhD

Role: primary

unovrl@unomaha.edu

402-554-3779

Other Identifiers

R01AG089307

Identifier Type: NIH

Identifier Source: secondary_id

View Link

0550-24-FB

Identifier Type: -

Identifier Source: org_study_id